Patents by Inventor Eli M. Wallace

Eli M. Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20220226326
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: August 23, 2021
    Publication date: July 21, 2022
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA
    Publication number: 20210015764
    Abstract: The present disclosure provides methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease. Compositions for use in these methods are also provided.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 21, 2021
    Applicant: Peloton Therapeutics Inc.
    Inventors: John A. Josey, Rajeev Shrimali, Eli M. Wallace, Tai Wong
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20200345735
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 7, 2020
    Publication date: November 5, 2020
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • Aromatic compounds and uses thereof
    Patent number: 10807948
    Abstract: Disclosed herein are substituted indane derivatives useful as HIF-2? inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2? activity are also disclosed.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 20, 2020
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Combination therapy of a HIF-2-? inhibitor and an immunotherapeutic agent and uses thereof
    Patent number: 10786480
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: September 29, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20200190031
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: 10597366
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF
    Publication number: 20190282535
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders.
    Type: Application
    Filed: April 24, 2019
    Publication date: September 19, 2019
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
    Patent number: 10335388
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 2, 2019
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • Compositions for use in treating pulmonary arterial hypertension
    Patent number: 10278942
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 7, 2019
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Xinlin Du, Barry Goggin
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20190119214
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: October 18, 2018
    Publication date: April 25, 2019
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Compositions for Use in Treating Pulmonary Arterial Hypertension
    Publication number: 20190015377
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 17, 2019
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: 10144711
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 4, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180334441
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Applicant: Array Biopharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen Laird, John Robinson, Shelley Allen
  • Benzimidazole derivatives and uses thereof
    Patent number: 10040767
    Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: August 7, 2018
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Hanbiao Yang
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 10017482
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: July 10, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen Laird, John Robinson, Shelley Allen
  • COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20180177754
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Application
    Filed: March 9, 2016
    Publication date: June 28, 2018
    Inventors: John A. JOSEY, Eli M. WALLACE, Xinlin DU, Barry GOGGIN
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20180169099
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 21, 2018
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • AROMATIC COMPOUNDS AND USES THEREOF
    Publication number: 20180162807
    Abstract: Aromatic entities that modulate HIF-2? activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2? activity are described herein.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 14, 2018
    Inventors: Darryl David DIXON, Jonas GRINA, John A. JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Rui Xu, Hanbiao YANG
  • Aryl ethers and uses thereof
    Patent number: RE49948
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: April 30, 2024
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang